Reprogenetics, Recombine, and Genesis Genetics Unite As Part of the CooperSurgical Family at ASRM 2016 Scientific Congress
October 17 2016 - 8:00AM
Business Wire
Reprogenetics, Recombine, and Genesis Genetics are pleased to
announce their joint presence as part of the CooperSurgical family
at the American Society for Reproductive Medicine (ASRM) Scientific
Congress and Expo, in Salt Lake City, Utah from October 15 to 19.
The companies are hosting a joint exhibit at booth 1607 in the Expo
Hall, showcasing their technology and test offerings for
pre-implantation genetic diagnosis and screening (PGD, PGS),
expanded carrier screening (ECS), and non-invasive prenatal
screening (NIPS).
In addition, the companies are holding their inaugural speaker
series at their satellite booth, 805. The series will include six
brief presentations by experts and practicing physicians in the
field of reproductive genetics, with opportunity for attendees to
engage in active discussion. Speakers will address some of the
latest topics, such as access to fertility care and the impact of
mosaicism. A schedule of talks and titles is available to view at
the booth.
As leaders in the field of reproductive genetic testing,
scientists from Reprogenetics, Recombine, and Genesis Genetics –
along with their clinical partners - are presenting thirty-six
accepted abstracts at the Scientific Congress, sixteen as oral and
twenty as poster presentations. Included in their presentations are
two award-winning abstracts. The paper “Transfer Fresh or Vitrify
After Blastocyst Biopsy? Results of an RCT” was selected as the
Society for Assisted Reproductive Technology (SART) Prize Paper.
First author Alison Coates of Oregon Reproductive Medicine will
give the presentation on Tuesday, October 18 at 11:15 AM MDT.
Selected as a Scientific Prize Paper, “Low Level Mosaicism:
Incidence and Implications on Clinical Pregnancies”, will be
presented by first author Dawn Kelk of Yale Fertility Center on
Tuesday, October 18 at 12:30 PM MDT.
“We are excited to hear the latest advances from the innovative
scientists across all three companies,” said Robert Auerbach, MD,
Executive Vice President, Chief Strategy and Medical Officer at
CooperSurgical. “Reprogenetics, Recombine, and Genesis Genetics
have driven the field of reproductive genetic testing, and we look
forward to using the power of this wealth of expertise to bring
even more advances to our clinical partners.”
About CooperVision
CooperVision, a unit of The Cooper Companies, Inc. (NYSE:COO),
is one of the world’s leading manufacturers of soft contact lenses.
The Company produces a full array of monthly, two-week and daily
disposable contact lenses, all featuring advanced materials and
optics. CooperVision has a strong heritage of solving the toughest
vision challenges such as astigmatism and presbyopia; and offers
the most complete collection of spherical, toric and multifocal
products available. Through a combination of innovative products
and focused practitioner support, the company brings a refreshing
perspective to the marketplace, creating real advantages for
customers and wearers. For more information,
visit www.coopervision.com.
About The Cooper Companies
The Cooper Companies, Inc. ("Cooper") is a global medical device
company publicly traded on the NYSE (NYSE:COO). Cooper is dedicated
to being A Quality of Life Company™ with a focus on delivering
shareholder value. Cooper operates through two business units,
CooperVision and CooperSurgical. CooperVision brings a refreshing
perspective on vision care with a commitment to developing a wide
range of high-quality products for contact lens wearers and
providing focused practitioner support. CooperSurgical is committed
to advancing the health of families with its diversified portfolio
of products and services focusing on women’s health, fertility and
diagnostics. Headquartered in Pleasanton, CA, Cooper has
approximately 10,000 employees with products sold in over 100
countries. For more information, please
visit www.coopercos.com.
View source
version on businesswire.com: http://www.businesswire.com/news/home/20161017005307/en/
Recombine, Inc.Sarah Yarnall,
855-687-4363sarahy@recombine.com
Cooper Companies (NYSE:COO)
Historical Stock Chart
From Aug 2024 to Sep 2024
Cooper Companies (NYSE:COO)
Historical Stock Chart
From Sep 2023 to Sep 2024